Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. Επικοινωνία Submitted by Δημήτρης Σπάχος on Πέμ, 04/30/2015 - 11:26
